LAWRENCEVILLE, N.J.,
Oct. 15, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) today announced that it
will host a Research and Development (R&D) Day for investors
and analysts on Tuesday, October 27,
2015. The event is scheduled to take place from 4:00 to 6:00 p.m. Eastern Time in New York City, and will be simultaneously
streamed as a webcast.
The presentations will focus on the Company's research and
development programs and will feature five leading experts in
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies, including:
- Donald Braun, Ph.D., Vice
President of Clinical Research, Cancer Treatment Centers of
America
- William Gerthoffer, Ph.D.,
Professor and Chair, Biochemistry and Molecular Biology,
University of South Alabama
- Charles A. Leath, III, M.D.,
MSPH, Associate Professor, Gynecologic Oncology, The University of Alabama School of Medicine of
UAB
- Bradley A. Maron, M.D.,
Assistant Professor of Medicine, Harvard
Medical School
- Premal Thaker, M.D., MS,
Associate Professor, Washington
University in St. Louis
A live webcast of the presentations will be available on
Celsion's website at http://investor.celsion.com/events.cfm
beginning at approximately 4:15 p.m. Eastern
Time. To ensure a timely connection, users should
register at least 15 minutes prior to the scheduled start. The
webcast will be archived for replay following the event for 90
days.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data, particularly
in small subgroups that are not statistically significant; FDA and
regulatory uncertainties and risks; the significant expense, time,
and risk of failure of conducting clinical trials; the need for
Celsion to evaluate its future development plans; possible
acquisitions or licenses of other technologies, assets or
businesses; possible actions by customers, suppliers, competitors,
regulatory authorities; and other risks detailed from time to time
in the Celsion's periodic reports and prospectuses filed with the
Securities and Exchange Commission. Celsion assumes no
obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or
otherwise.
Celsion Investor Contact
Jeffrey W. Church
Senior Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion Media Contacts
860-483-1721
Harriet Shelare
Director, Communications
hshelare@celsion.com
Bill Berry
Berry & Company
212-253-8881
bberry@berrypr.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-to-host-research-and-development-day-on-october-27-2015-300159936.html
SOURCE Celsion Corporation